Lei Fang

Co-founder, Chairman & CEO at Excalipoint Therapeutics

Presenter

Dr. Lei Fang is a biotech entrepreneur, immunologist, and drug developer focused on advancing next-generation cancer immunotherapies. He is the Co-founder and Chairman of Excalipoint Therapeutics, where he leads the company's strategic vision, scientific direction, and the development of innovative T-cell engager (TCE) therapies designed to unlock the full potential of T-cell-mediated cancer treatment. Dr. Fang has more than a decade of experience in oncology drug development, translational medicine, and innovative biologics. His work focuses on translating advances in immunology into differentiated therapeutic platforms capable of delivering more precise, potent, and durable immune therapies for patients with cancer. Prior to founding Excalipoint Therapeutics, Dr. Fang served as Vice President of Lepu Biopharma and CEO of CtM Bio, where he led development strategy and early clinical programs for innovative oncology biologics, including TCE therapies. Previously, he was Co-founder of I-Mab (NASDAQ: IMAB), where he contributed to the advancement of multiple innovative biologics and supported the company's growth into a globally recognized biotechnology company. Earlier in his career, Dr. Fang worked at GSK (GlaxoSmithKline) R&D China as a scientist focused on autoimmune drug discovery and translational medicine. During this time, he gained extensive experience in global pharmaceutical research and development and the integration of basic science with clinical drug translation. Dr. Fang received his Ph.D. in Cell Biology from the Chinese Academy of Sciences. He is recognized for his expertise in T-cell engager biology, translational immunology, and early clinical development of innovative cancer therapies, and is committed to building global biotechnology platforms capable of delivering transformative medicines for patients worldwide.